Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 09/26 04:59:36 pm
296.2 DKK   -0.20%
09/26 NOVO NORDISK A/ : submits application in the US for including data f..
09/26 NOVO NORDISK A/ : - Share repurchase programme
09/23 NOVO NORDISK A/ : submits application in the US for including data f..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity.

The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas.

The company was founded in 1923 by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen and is headquartered in Bagsværd, Denmark.

Number of employees : 40 638 persons.
Sales per Businesses
20142015Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care69,98078.8%85,59079.3% +22.31%
Biopharmaceuticals18,82621.2%22,33720.7% +18.65%
Sales per Regions
20142015Delta
DKK (in Million)%DKK (in Million)%
North America43,12348.6%56,85752.7% +31.85%
Europe20,15022.7%20,79819.3% +3.22%
International12,54014.1%14,96613.9% +19.35%
China8,0889.1%9,8719.1% +22.05%
Japan & Korea4,9055.5%5,4355% +10.81%
Managers
NameAgeSinceTitle
Lars Rebien Sørensen621982President & Chief Executive Officer
Göran Ando672005Chairman
Jesper Brandgaard, MBA531999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD561991Chief Science Officer & Executive Vice President
Alan C. Moses, MD-2008Global Chief Medical Officer
Mads Krogsgaard--Chief Science Officer
Anne Marie Handrup Kverneland601981Director
Stig Strøbæk521992Director
Bruno Francois Jules Angelici, MBA692011Independent Non-Executive Director
Thomas Paul Koestler, PhD652011Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 2,112,564,000 1,796,581,297 85.0% 52,168,703 2.5% 67.8%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.14%
Capital Research & Management Co. (World Investors) 155,914,056 7.75%
The Vanguard Group, Inc. 37,613,482 1.87%
Norges Bank Investment Management 36,416,979 1.81%
Carmignac Gestion SA 27,869,686 1.38%
Novo Nordisk A/S 27,546,648 1.37%
Northern Cross LLC 27,431,187 1.36%
BlackRock Investment Management (UK) Ltd. 21,463,464 1.07%
Alecta Pension Insurance Mutual 20,908,000 1.04%
BlackRock Fund Advisors 16,434,957 0.82%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 27,546,6481.37%1,288,994,983 USD
Nnit A/S (NNIT) 6,375,00025.5%214,643,254 USD
Innate Pharma (IPH) 5,422,70810.1%62,267,655 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S-25.78%89 965
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
GLAXOSMITHKLINE PLC20.39%103 357
SANOFI-14.01%97 974
ALLERGAN PLC-23.62%94 506
BRISTOL-MYERS SQUIBB C..-19.35%92 699
ELI LILLY AND CO-5.63%87 778
ASTRAZENECA PLC11.99%83 672
BAYER AG-21.00%82 947
ABBOTT LABORATORIES-7.19%61 269
SHIRE PLC8.98%59 910
TAKEDA PHARMACEUTICAL ..-19.32%37 934
ASTELLAS PHARMA INC-7.48%33 941
MYLAN NV-23.84%22 028
CHUGAI PHARMACEUTICAL ..-12.35%20 281
EISAI CO., LTD-18.84%18 882
SHIONOGI & CO LTD-5.87%17 803
Sector Pharmaceuticals - NEC
Novo Nordisk A/S : Connections
Novo Nordisk China Pharmaceuticals Co. Ltd.
Novo Nordisk Invest 2 A/S
Archimedes Pharma UK Ltd.
Essex Bidco Ltd.
Novo A/S
Bio*One Capital Pte Ltd.
Novo Nordisk Region North America Ii A/S
EUSA Pharma (Europe) Ltd.
University of Copenhagen
Carlsberg Breweries A/S
RAND Health
The International Centre for Missing & Exploited Children
Novo Nordisk Pharmaceuticals A/S
Essex Woodlands Health Ventures UK Ltd.
Novo Nordisk Region China A/S
SWMF Life Science Venture Fund LP
Novo Nordisk Holding Ltd.
Melinta Therapeutics, Inc.
Steno Diabetes Center A/S
Novo Nordisk Fonden
New England Healthcare Institute
Vatera Holdings LLC
Bertelsmann Management SE
Symphogen A/S
Danmarks Nationalbank
Pearl Therapeutics, Inc.
Novo Nordisk Region Japan & Korea A/S
Edgemont Pharmaceuticals LLC
Novo Nordisk Region Europe A/S
Novo Nordisk Region International Operations A/S
ImmusanT, Inc.
Novo Nordisk Gsc Holding A/S
Arisaph Pharmaceuticals, Inc.
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsværd, Capital Region 2880

Phone : +45.44.44.88.88
Fax : +45.44.49.05.55
Web : www.novonordisk.com
© 2016 People , Fundamentals and Ownership